ES2599781T3 - Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen - Google Patents
Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen Download PDFInfo
- Publication number
- ES2599781T3 ES2599781T3 ES10715912.1T ES10715912T ES2599781T3 ES 2599781 T3 ES2599781 T3 ES 2599781T3 ES 10715912 T ES10715912 T ES 10715912T ES 2599781 T3 ES2599781 T3 ES 2599781T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- cells
- amino acid
- zero
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 17
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title description 17
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title description 17
- 239000000203 mixture Substances 0.000 title description 11
- 230000003712 anti-aging effect Effects 0.000 title description 4
- 230000003213 activating effect Effects 0.000 title description 2
- 102000004196 processed proteins & peptides Human genes 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000004475 Arginine Substances 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- -1 or equals zero Substances 0.000 abstract 1
- 150000003141 primary amines Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 210000002510 keratinocyte Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 102000005936 beta-Galactosidase Human genes 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108010004108 peptidylglutamylpeptide hydrolase Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000006315 carbonylation Effects 0.000 description 4
- 238000005810 carbonylation reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102400000827 Saposin-D Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- FOYHOBVZPWIGJM-KCHLEUMXSA-N (4s)-4-[[(2s)-4-methyl-2-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]-5-[(4-methyl-2-oxochromen-7-yl)amino]-5-oxopentanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 FOYHOBVZPWIGJM-KCHLEUMXSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0901614 | 2009-04-02 | ||
| FR0901614A FR2944018B1 (fr) | 2009-04-02 | 2009-04-02 | Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant |
| PCT/FR2010/000277 WO2010112710A2 (fr) | 2009-04-02 | 2010-04-01 | Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2599781T3 true ES2599781T3 (es) | 2017-02-03 |
Family
ID=41328482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10715912.1T Active ES2599781T3 (es) | 2009-04-02 | 2010-04-01 | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8530622B2 (enExample) |
| EP (1) | EP2414381B1 (enExample) |
| JP (1) | JP5728466B2 (enExample) |
| CN (1) | CN102428095B (enExample) |
| ES (1) | ES2599781T3 (enExample) |
| FR (1) | FR2944018B1 (enExample) |
| WO (1) | WO2010112710A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2514403A1 (en) * | 2011-04-20 | 2012-10-24 | Coty Germany GmbH | Cosmetic composition for increasing the collagen synthesis in the skin cells |
| EP2810934A1 (en) | 2013-06-09 | 2014-12-10 | Symrise AG | New succinate derivatives |
| CN108350030B (zh) * | 2015-09-10 | 2022-12-13 | 汉阳大学校产学协力团 | 皮肤可渗透肽及其使用方法 |
| JP7191386B2 (ja) * | 2017-02-24 | 2022-12-19 | リポトゥルー，エセ．エレ． | 化粧料に使用するためのペプチドおよび組成物 |
| PL3831358T3 (pl) * | 2019-12-04 | 2025-08-04 | Lipotrue, S.L. | Peptydy i kompozycje do stosowania w kosmetyce i medycynie |
| JP2022012379A (ja) * | 2020-07-01 | 2022-01-17 | 国立大学法人富山大学 | ユビキチン－プロテアソーム系の活性化剤、およびその利用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2704754B1 (fr) | 1993-05-07 | 1995-06-30 | Oreal | Utilisation d'un alkyle ester de glutathion dans une composition cosmetique ou dermatologique destinee au traitement par voie topique du vieillissement cutane. |
| WO2000004042A1 (fr) * | 1998-07-15 | 2000-01-27 | Sumitomo Electric Industries, Ltd. | Composes peptidiques |
| FR2822701B1 (fr) | 2001-04-03 | 2005-03-18 | Lvmh Rech | Utilisation d'un extrait d'algue phaeodactylum comme agent cosmetique favorisant l'activite du proteasome des cellules de la peau et composition cosmetique le contenant |
| WO2003055448A2 (en) * | 2001-12-21 | 2003-07-10 | Achillion Pharmaceuticals, Inc. | Antifungal compositions |
| US20050282747A1 (en) | 2003-10-01 | 2005-12-22 | The Research Foundation Of State University Of New York At Stony Brook | Methods and compositions for wound healing |
| FR2864085B1 (fr) | 2003-12-18 | 2010-09-17 | Centre Nat Rech Scient | Nouveaux modulateurs du proteasome |
| FR2869228B1 (fr) | 2004-04-21 | 2008-09-05 | Vincience Sa | Utilisation d'un hydrolysat de proteines de cruciferes en tant qu'agent depigmentant dans ou pour une composition cosmetique et/ou pharmaceutique |
| US7919468B2 (en) | 2005-04-07 | 2011-04-05 | Centre National De La Recherche Scientifique (C.N.R.S.) | Compounds useful as modulators of the proteasome activity |
| JP3914244B2 (ja) | 2005-10-03 | 2007-05-16 | 株式会社ファンケル | 異常タンパク質除去用組成物 |
| FR2898808B1 (fr) | 2006-03-27 | 2008-05-02 | Biotechmarine Soc Par Actions | "principe actif cosmetique compose de ferrulate d'arginine et d'un extrait de microalgue et ses utilisations". |
| BRPI0712073B8 (pt) * | 2006-05-17 | 2021-05-25 | Hoffmann La Roche | ácido nucléico para produção de um polipeptídio ou proteína heteróloga |
| FR2903903B1 (fr) | 2006-07-18 | 2008-08-29 | Expanscience Laboratoires Sa | Utilisation d'un hydrolysat de proteines de riz en tant que principe actif pigmentant |
| FR2904552B1 (fr) | 2006-08-03 | 2012-09-21 | Soc Extraction Principes Actif | Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes |
| WO2008015343A2 (fr) | 2006-08-03 | 2008-02-07 | Societe D'extraction Des Principes Actifs Sa (Vincience) | Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes |
| FR2915381B1 (fr) | 2007-04-27 | 2012-06-08 | Vincience | Utilisation d'un principe actif issu du soja (glycine max l) pour preparer une composition destinee a activer le cytochrome c |
| FR2915384B1 (fr) | 2007-04-27 | 2010-01-15 | Vincience | Utilisation d'un principe actif issu du soja (glycine maxl.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs. |
| FR2915382B1 (fr) | 2007-04-27 | 2012-06-01 | Vincience | Utilisation d'un principe actif issu du mais (zea mays l) pour preparer une composition destinee a activer le cytochrome c |
| FR2915380B1 (fr) | 2007-04-27 | 2012-06-08 | Vincience | Utilisateur d'un principe actif issu du riz (oryza sativa l) pour preparer une composition destinee a activer le cytochrome c |
| FR2915379B1 (fr) | 2007-04-27 | 2012-07-13 | Vincience | Utilisation d'un principe actif issu du riz (oryza sativa l) pour preparer une composition destinee a proteger les mitochondries |
| FR2915383B1 (fr) | 2007-04-27 | 2010-01-15 | Vincience | Utilisation d'un principe actif issu du riz (oryza sativa l.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs. |
| FR2915378B1 (fr) | 2007-04-27 | 2009-08-21 | Vincience Sa | Utilisation d'un principe actif issu du soja (glycine max l.) pour preparer une composition destinee a proteger les mitochondries |
-
2009
- 2009-04-02 FR FR0901614A patent/FR2944018B1/fr not_active Expired - Fee Related
-
2010
- 2010-04-01 CN CN201080021998.3A patent/CN102428095B/zh not_active Expired - Fee Related
- 2010-04-01 US US13/262,305 patent/US8530622B2/en active Active
- 2010-04-01 ES ES10715912.1T patent/ES2599781T3/es active Active
- 2010-04-01 WO PCT/FR2010/000277 patent/WO2010112710A2/fr not_active Ceased
- 2010-04-01 EP EP10715912.1A patent/EP2414381B1/fr active Active
- 2010-04-01 JP JP2012502731A patent/JP5728466B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5728466B2 (ja) | 2015-06-03 |
| CN102428095B (zh) | 2015-04-08 |
| US8530622B2 (en) | 2013-09-10 |
| FR2944018A1 (fr) | 2010-10-08 |
| CN102428095A (zh) | 2012-04-25 |
| EP2414381A2 (fr) | 2012-02-08 |
| EP2414381B1 (fr) | 2016-08-10 |
| WO2010112710A2 (fr) | 2010-10-07 |
| JP2012522757A (ja) | 2012-09-27 |
| WO2010112710A3 (fr) | 2010-11-25 |
| US20120040912A1 (en) | 2012-02-16 |
| FR2944018B1 (fr) | 2012-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2599781T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
| CA2993227C (en) | Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair | |
| ES2838548T3 (es) | Procedimiento de identificación de marcadores moleculares de la piel de niño | |
| Mah et al. | Elevated CD26 expression by skin fibroblasts distinguishes a profibrotic phenotype involved in scar formation compared to gingival fibroblasts | |
| PE20010693A1 (es) | Metodo para la determinacion de actividad alfa-secretasa sobre la app | |
| ES2537346T3 (es) | Hidrolizados peptídicos activadores del proteasoma y composiciones que los contienen | |
| JP2021518331A (ja) | 細胞加齢の反転のための一過性細胞リプログラミング | |
| US11892447B2 (en) | Method for evaluating the effects of dehydration on children's skin | |
| Wang et al. | Secretome of human umbilical cord mesenchymal stem cell maintains skin homeostasis by regulating multiple skin physiological function | |
| US11604184B2 (en) | Juvenile atopic dermatitis models | |
| Reynolds et al. | Biological effects of air pollution on the function of human skin equivalents | |
| ES2498674T3 (es) | Métodos para medir la viabilidad celular sin usar células de control | |
| ES2532545T3 (es) | Nuevos péptidos que intervienen en la vía de señalización de SCF c-Kit y composiciones que los comprenden | |
| EP2413891B1 (fr) | Peptides anti-age activateurs du proteasome et compositions les contenant | |
| ES2769839T3 (es) | Composiciones que comprenden un activador de sirt6 y una enzima de reparación de ADN | |
| Holtz | In vitro methods to screen materials for anti-aging effects | |
| CN107405278B (zh) | 序列为his-d-trp-ala-trp-d-phe-lys-nh2的肽用于减少或延缓细胞衰老的出现和皮肤老化的迹象的用途 | |
| US20180161262A1 (en) | Cosmetic Method and Dermatological Topical Agent for Use Therein, Migration Imparting Agent, and Method for Screening Components for Use in Cosmetic Method for Improving Skin State | |
| Prokopov et al. | Effect of a hyaluronic acid‐based mesotherapeutic injectable on the gene expression of CLOCK and Klotho proteins, and environmentally induced oxidative stress in human skin cells | |
| TWI586358B (zh) | Extraction of bleomycin extract, angelica extract, cork extract, wild sesame extract, rosemary extract, benzenesulfonyl GABA and erythritol for the manufacture of bleomycin hydrolyzate production accelerator | |
| Kato et al. | Inhibition of sea urchin fertilization by jaspisin, a specific inhibitor of matrix metalloendoproteinase | |
| CN102947323B (zh) | 新的胱天蛋白酶-14激活肽及包含所述激活肽的组合物 | |
| JP7474736B2 (ja) | 白斑の予防又は改善剤の評価又は選択方法 | |
| Yokota et al. | Effects of proteasome inhibitors on fertilization of the sea urchin Anthocidaris crassispina | |
| Cressman | Investigating Mechanisms of Impaired Mineralization Due to Deficient Spermine Synthase Activity |